HistoSonics Secures $2.25B Investment Led by Bezos Expeditions and Johnson & Johnson’s JJDC to Accelerate Global Rollout of Edison Histotripsy Platform

8Month7Day,HistoSonicsAnnounced the completion of a controlling equity transfer transaction, with its majority equity held byK5 Global、Bezos ExpeditionsAndWellington ManagementA consortium of investors composed of...The transaction valuation is22.5Billion US dollars(Approximately RMB160100 million)。

As Histotripsy Therapy (histotripsy) Representative Enterprise of Technology,HistoSonicsThe introduction of diverse capital parties this time, while maintaining private operation, also benefits its core products.EdisonThe global deployment and expansion of indications provide further impetus.

01

HistoSonicsStill Choose the "Independent Growth" Path

According to the official announcement, this transaction was conducted byHistoSonicsLed by the current management team, consortium investors includeK5 Global、Bezos Expeditions(Jeff Bezos's personal investment company),Wellington Management、JJDC(Johnson & Johnson Ventures),Alpha Wave Ventures、Amzak Health、HealthQuest Capital、Lumira Ventures、Venture InvestorsandState of Wisconsin Investment Boardetc. Traded at2025Year8Month6was officially completed on [date].

Despite the transaction amount being as high as22.5billion dollars, the company will continue to remain a privately held company and be led by the current president and CEO.Mike BlueContinue to lead the team in advancing commercialization, indication expansion, and global market deployment.

BlueStated: "We chose this capital path in order to delayIPOAccelerate growth and product implementation under the state to ensureHistoSonics"Not only becoming a technology company, but also an industry platform capable of restructuring the paradigm of surgical treatment."

It is worth noting that,This valuation has already madeHistoSonicsBecoming one of the largest medtech deals in the U.S. Midwest and the latest "unicorn" company in Michigan (valued at over10(Billion USD), and the logic supporting this valuation isEdisonThe system's high degree of differentiation in clinical pathways and technical paradigms.

02

Open New Ways for Tumor Treatment

HistoSonicsCore ProductEdison, isThe world's first to obtainFDA De NovoLicensed Tissue Acoustic Treatment Platform System. Unlike thermal ablation, radiotherapy, or chemotherapy,EdisonUsing high-amplitude, ultra-short pulse focused ultrasound, through "bubble cloud(Bubble Cloud)" principle, achieving targeting of tissues at the subcellular levelMechanical Disruption。

Its biggest feature is——Non-thermal, Non-toxic, Non-incision。

During the treatment process,EdisonThrough imaging guidance, focused ultrasound energy is precisely delivered to the tumor area without causing thermal damage, and without the need for puncture or surgical resection. The entire treatment process is controlled by a robotic arm, combined withCTThree-dimensional targeting with real-time ultrasound imaging can effectively avoid damage to healthy tissue.

This pathway was first developed by bioengineering researchers at the University of Michigan.Zhen XuDr.2001Proposed in the year and in the past20Mid-year byHistoSonicsThe team drives the implementation of engineering, productization, and commercialization.

Currently,EdisonSystem indications have coveredLiver Tumor Treatment, is its first to obtainFDAAuthorized clinical application directions. In addition,HistoSonicsInitiated for kidney tumors (HOPE4KIDNEY，NCT05820087) and pancreatic tumors (GANNON，NCT06282809) clinical trials, with plans to expand to the treatment of prostate cancer and benign diseases.

In the U.S. market,EdisonThe system has been deployed in China.50Home Medical Center, with cumulative treatments exceeding2000Number of patients. According to the company's plan,2025To be additionally installed before the end of the year50A system.

03

Targeting the "Next-Generation Robotic Surgical Platform"

Despite previous media reports, including Medtronic,GEIncluding Johnson & Johnson, several strategic investors have expressed potential acquisition interest,HistoSonicsUltimately, the choice was made for a consortium-type investor to take control, rather than merging into a large medical technology group. This decision reflects the management's clear judgment that the company should maintain an independent development path.

According to "Crain’s Detroit Business" reported,Blueand his team believe that,EdisonThe system's market potential and platform scalability far exceed traditional ones.30-50The billion-dollar acquisition bid hopes to achieve a delayIPO, to gain more valuation space - by analogyIntuitive SurgicalThe development path.

K5 GlobalCo-founderBryan BaumSaid: "HistoSonicsThe highlight is not only in the technology itself, but in the speed and clarity with which its team transforms breakthrough technology into clinical reality. Hospitals continue to place orders, patient demand is surging, and clinical data is overwhelmingly convincing. We believe,HistoSonics"Already standing at the entrance of the next technological revolution in healthcare."

It is estimated thatHistoSonics 2025Annual revenue will exceed1Billion US dollars,2026Expected to increase to2Billion US dollars,ShowcasedEdisonThe system's rapid scaling capability in terms of clinical acceptance and market penetration.

04

From "Robotic Surgery" to "Mechanical Energy Therapy"

From the perspective of medical technology evolution, histotripsy treatment (Histotripsy) represents aNew Category of Non-Invasive Treatment Pathways。Compared with current thermal ablation (such as radiofrequency, microwave), chemotherapy, or traditional surgery,EdisonThe system has the following technical advantages:

No Thermal Damage:Avoid tissue carbonization or damage to surrounding structures;

Mechanical Removal:Capable of achieving subcellular-level destruction, suitable for complex anatomical regions;

Non-invasive procedure:No puncture, incision, or catheterization required, with short patient recovery time;

Robot Precision Guidance：Combined with the imaging fusion platform, improve the accuracy of targeting.

This makesEdisonParticularly suitable for complex tumors with "poor surgical accessibility," such as those located in the deep liver, renal hilum area, and pancreatic tail. It also demonstrates potential for technical extension in fields like pediatric tumors and functional diseases (e.g., benign prostatic hyperplasia) in the future.

At the market level, according toPitchbookData shows that its main competitors includeProfound Medical、Insightec、ViewRayAndVarian Medical Systems, etc., but there is currently no system with a fully mechanically disruptive pathway.HistoSonicsThehistotripsyThe platform is highly differentiated in terms of principles and technical mechanisms.

05

The Path of Medical Insurance Continues to Open

HistoSonicsNot only has it been widely deployed in the United States, but it has also recently been implemented at Cambridge University Hospitals in the UK (Addenbrooke’s Hospital) Launch the first tissue acoustic therapy center in Europe, with plans to gradually enter high-end markets with high acceptance of advanced devices such as Germany, Italy, and Japan.

In terms of医保可及性, Goldman Sachs Blue Cross Blue Shield (Highmark Blue Cross Blue Shield) has been approved for use in New York, Pennsylvania, Delaware, and West Virginia.EdisonCommercial Insurance Payment for Systemic Treatment of Liver Tumors Covers a Population Exceeding700Million, paving the way for its large-scale promotion.

In addition, the company is communicating with medical payers in multiple states to explore the inclusion of tissue sonic treatment in pay-for-performance (Value-based Care) orDRGSystem Possibilities.

06

Conclusion

CorrectHistoSonicsFor them, this deal is more like a phased confirmation rather than a final "exit."

Technical mechanisms have been successfully implemented, clinical feedback is continuously accumulating, and global implementation and medical insurance systems are proceeding simultaneously.——EdisonThe system is no longer just "conceptually advanced" but is beginning to demonstrate real industrial traction.

This also explains why, after multiple strategic acquisition intentions emerged, the management still chose to stick to privatization and postpone.IPO, and a group of diversified capital took over the controlling stake: what they are betting on is not just a machine, but an open enough surgical system platform.

END